Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Taiho Oncology, Inc.
ToLymph Inc.
George Washington University
Emory University
Eastern Cooperative Oncology Group
Boston Scientific Corporation
AstraZeneca
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
Shanghai Pulmonary Hospital, Shanghai, China
University of California, San Diego
Emory University
AstraZeneca
NRG Oncology
NATCO Pharma Ltd.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Yonsei University
Iovance Biotherapeutics, Inc.
Mayo Clinic
Cedars-Sinai Medical Center
University of Kentucky
M.D. Anderson Cancer Center
Thomas Jefferson University
Genelux Corporation
Institut Bergonié
Leiden University Medical Center
Fudan University
University of California, San Diego
GlaxoSmithKline
Verrica Pharmaceuticals Inc.
Situs Cancer Research Center
Sun Yat-sen University
Regeneron Pharmaceuticals
University Health Network, Toronto
University of Utah
University of California, San Francisco
Replimune Inc.
Jinling Hospital, China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Eastern Cooperative Oncology Group
Hoosier Cancer Research Network
Catalysis SL
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The First Affiliated Hospital with Nanjing Medical University
Second Affiliated Hospital of Soochow University